BRPI0807626A2 - Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase - Google Patents

Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase

Info

Publication number
BRPI0807626A2
BRPI0807626A2 BRPI0807626-0A2A BRPI0807626A BRPI0807626A2 BR PI0807626 A2 BRPI0807626 A2 BR PI0807626A2 BR PI0807626 A BRPI0807626 A BR PI0807626A BR PI0807626 A2 BRPI0807626 A2 BR PI0807626A2
Authority
BR
Brazil
Prior art keywords
aminotiazole
synthesis
compounds
kinase inhibitors
kinase
Prior art date
Application number
BRPI0807626-0A2A
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
Francois Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of BRPI0807626A2 publication Critical patent/BRPI0807626A2/pt
Publication of BRPI0807626B1 publication Critical patent/BRPI0807626B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0807626-0A 2007-02-13 2008-02-13 Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase BRPI0807626B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
US60/889,587 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
BRPI0807626A2 true BRPI0807626A2 (pt) 2014-11-25
BRPI0807626B1 BRPI0807626B1 (pt) 2022-03-03

Family

ID=39332208

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807626-0A BRPI0807626B1 (pt) 2007-02-13 2008-02-13 Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase

Country Status (23)

Country Link
US (3) US8153792B2 (pt)
EP (2) EP2118099B1 (pt)
JP (2) JP5568312B2 (pt)
KR (1) KR20090110851A (pt)
CN (2) CN103342701B (pt)
AR (1) AR065337A1 (pt)
AT (1) ATE515506T1 (pt)
AU (1) AU2008214679A1 (pt)
BR (1) BRPI0807626B1 (pt)
CA (2) CA2677586C (pt)
ES (2) ES2369617T3 (pt)
HR (2) HRP20110709T1 (pt)
IL (1) IL200320A0 (pt)
MA (1) MA31180B1 (pt)
MX (1) MX2009008665A (pt)
NZ (1) NZ578944A (pt)
PL (2) PL2118099T3 (pt)
RU (2) RU2456285C2 (pt)
SI (2) SI2366703T1 (pt)
TN (1) TN2009000342A1 (pt)
TW (1) TWI406862B (pt)
WO (1) WO2008098949A2 (pt)
ZA (1) ZA200905981B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
AR080048A1 (es) 2010-01-28 2012-03-07 Ab Science Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib
WO2011092338A1 (en) 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
WO2011151372A1 (en) 2010-06-02 2011-12-08 Ab Science Treatment of rheumatoid arthritis with masitinib
US20140147415A1 (en) 2010-11-05 2014-05-29 Ab Science Treatment of mastocytosis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
AR085934A1 (es) 2011-04-08 2013-11-06 Ab Science Tratamiento de mieloma multiple con masitinib
US10238649B2 (en) 2012-10-04 2019-03-26 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
WO2015082496A1 (en) 2013-12-02 2015-06-11 Ab Science Use of masitinib for treatment of colorectal cancer
EP2886543A1 (en) 2013-12-18 2015-06-24 Sandoz Ag Crystalline form of mastinib mesylate
US20170196853A1 (en) 2014-06-02 2017-07-13 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
WO2017016512A1 (zh) * 2015-07-29 2017-02-02 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
EP3359195B1 (en) 2015-10-05 2024-05-29 AB Science Treatment of severe systemic mastocytosis with masitinib
SG11201808106YA (en) 2016-03-25 2018-10-30 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
WO2018177854A1 (en) 2017-03-31 2018-10-04 Sandoz Ag Crystalline form of masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2021099616A1 (en) 2019-11-22 2021-05-27 Ab Science Masitinib for the treatment of sickle cell disease
EP3831384A1 (en) 2019-12-02 2021-06-09 AB Science Use of masitinib for the treatment of eosinophilic asthma
CN115515590A (zh) 2020-02-20 2022-12-23 Ab科学有限公司 马赛替尼用于治疗多发性硬化患者亚群
CN115867278B (zh) 2020-04-10 2025-02-28 Ab科学有限公司 马赛替尼用于治疗covid-19的用途
US20240058328A1 (en) 2020-12-16 2024-02-22 Ab Science Masitinib for the treatment of alzheimer's disease
MX2023013781A (es) 2021-05-17 2023-12-04 Ab Science Masitinib para el tratamiento del cancer de prostata resistente a la castracion.
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
PL342447A1 (en) * 1997-10-27 2001-06-04 Agouron Pharma Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
AU779908B2 (en) * 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003002109A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
EP1401429A2 (en) 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
WO2003003006A2 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004537542A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
US20040266797A1 (en) 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
EP1401411A2 (en) 2001-06-29 2004-03-31 AB Science Use of tyrosine kinase inhibitors for treating bone loss
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
US20040259892A1 (en) 2001-06-29 2004-12-23 Alain Moussy Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
EP1461032B1 (en) 2001-09-20 2008-07-16 AB Science Use of c-kit inhibitors for promoting hair growth
ATE388711T1 (de) 2001-09-20 2008-03-15 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
EP1427422A1 (en) 2001-09-20 2004-06-16 AB Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
DE60307237T2 (de) 2002-02-27 2007-10-18 Ab Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
EP1490067B1 (en) 2002-02-27 2008-09-17 AB Science Use of tyrosine kinase inhibitors for treating substance use disorders
MXPA04011579A (es) * 2002-05-29 2005-03-07 Amgen Inc Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular.
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
JP2006517234A (ja) * 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
CA2517308A1 (en) 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
ATE395052T1 (de) 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
BRPI0418074B8 (pt) 2003-12-25 2021-05-25 Nippon Shinyaku Co Ltd derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
KR20090110851A (ko) 2009-10-22
US8492545B2 (en) 2013-07-23
US8940894B2 (en) 2015-01-27
CA2970628C (en) 2019-08-27
EP2118099B1 (en) 2011-07-06
PL2118099T3 (pl) 2011-12-30
CA2677586C (en) 2017-07-25
NZ578944A (en) 2011-03-31
CA2970628A1 (en) 2008-08-21
EP2366703A1 (en) 2011-09-21
ES2522169T3 (es) 2014-11-13
CN103342701A (zh) 2013-10-09
EP2118099A2 (en) 2009-11-18
RU2009132186A (ru) 2011-03-20
MX2009008665A (es) 2009-08-21
RU2456285C2 (ru) 2012-07-20
JP5784073B2 (ja) 2015-09-24
US20120196871A1 (en) 2012-08-02
CN101657446A (zh) 2010-02-24
ZA200905981B (en) 2010-11-24
SI2366703T1 (sl) 2014-10-30
ATE515506T1 (de) 2011-07-15
HRP20110709T1 (hr) 2011-11-30
IL200320A0 (en) 2010-04-29
SI2118099T1 (sl) 2011-11-30
WO2008098949A2 (en) 2008-08-21
JP2010518141A (ja) 2010-05-27
BRPI0807626B1 (pt) 2022-03-03
JP5568312B2 (ja) 2014-08-06
EP2366703B1 (en) 2014-07-30
WO2008098949A3 (en) 2008-10-02
CN103342701B (zh) 2016-09-21
US8153792B2 (en) 2012-04-10
PL2366703T3 (pl) 2015-02-27
TW200848419A (en) 2008-12-16
TWI406862B (zh) 2013-09-01
HRP20140986T1 (hr) 2014-11-21
ES2369617T3 (es) 2011-12-02
AR065337A1 (es) 2009-06-03
AU2008214679A1 (en) 2008-08-21
RU2491286C1 (ru) 2013-08-27
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
US20130289045A1 (en) 2013-10-31
TN2009000342A1 (en) 2010-12-31
CA2677586A1 (en) 2008-08-21
CN101657446B (zh) 2013-05-15
JP2013177437A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
BRPI0807626A2 (pt) Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
BRPI0920356A2 (pt) Processo para a preparação de compostos úteis como inibidores de sglt
BRPI0810452A2 (pt) Processo para a produção de composições de betume
BRPI1006794A2 (pt) Processo para preparar inibidores jak e compostos intermediários relacionados
BRPI0911254A2 (pt) processo para a preparação de um composto
BRPI0910910A2 (pt) processo para preparar um composto
BRPI0910911A2 (pt) processo para preparar um composto
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI0812567A2 (pt) Processo para produção de hidrocarbonetos ramificados
BRPI0819659A2 (pt) Processo para produção de álcool
BRPI0811156A2 (pt) compostos antagonistas de rna para a modulação de her3
BRPI0810067A2 (pt) Processo para a preparação de capecitabina
BRPI0809652A2 (pt) Processo melhorado para a síntese de solifenacina
BRPI1012018A2 (pt) processo para preparar um composto
BRPI0912475A8 (pt) compostos como inibidores de quinase
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0719955A2 (pt) Processo para síntese de derivados de fenóxi diaminopirimidina
BRPI0921420A2 (pt) processo para preparar compostos
BRPI1013830A2 (pt) Processo para a iodação de compostos aromáticos
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BRPI0910675A2 (pt) Processo para preparação de intermediários de naftalen-2-ilpirazol-3-ona úteis na síntese dos inibidores de receptores sigma
BRPI1008117A2 (pt) Processo para a sintese de cleistantina
BRPI0914556A2 (pt) Processo para a preparação de compostos de piperazina substituídos por cicloalquila

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 417/04

Ipc: C07D 417/04 (2006.01), A61P 13/10 (2006.01), A61P

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2866 DE 09-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.